Article Information
History
- February 9, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Markku Lähteenvuo, MD, PhD*,1,
- Jurjen J. Luykx, MD, PhD*,2,3,4,†,
- Heidi Taipale, PhD1,5,6,
- Ellenor Mittendorfer-Rutz, PhD5,
- Antti Tanskanen, PhD1,5,
- Albert Batalla, MD, PhD2 and
- Jari Tiihonen, MD, PhD1,5,7
- 1Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Niuvankuja 65, 70240, Kuopio, Finland
- 2Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
- 3Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands
- 4Second opinion outpatient clinic, GGNet Mental Health, Warnsveld, The Netherlands
- 5Karolinska Institutet, Department of Clinical Neuroscience, Division of Insurance Medicine, Berzelius väg 3. 171 77 Stockholm, Sweden
- 6University of Eastern Finland, School of Pharmacy, Yliopistonranta 1, 70210, Kuopio, Finland
- 7Center for Psychiatry Research, Norra Stationsgatan 69, 11364 Stockholm, Sweden
- ↵†Corresponding author:
Dr. Jurjen Luykx, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands, j.luykx{at}maastrichtuniversity.nl.
↵* equal contribution
Posted February 09, 2022.
Associations between antipsychotic use, substance use and relapse risks in patients with schizophrenia - real-world evidence from two national cohorts
